dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts

Annals of the Rheumatic Diseases

Volumn 70, Issue 3, 2011, Pages 544-550

  Farina, Giuseppina ^a   York, Michael ^a   Collins, Cindy ^a   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOUBLE STRANDED RNA; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN 2; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN KINASE R; RETINOIC ACID INDUCIBLE PROTEIN I; RNA HELICASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL INJURY; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FIBROBLAST; GENE DELETION; HUMAN; HUMAN CELL; LUNG ARTERY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; IMMUNITY, INNATE; LIGANDS; MICE; MICE, INBRED C57BL; POLY I-C; PULMONARY ARTERY; RNA, DOUBLE-STRANDED; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TOLL-LIKE RECEPTOR 3;

EID: 79951512704     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.132464     Document Type: Article

References (56)

1. Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 1997;36:272-5. (Pubitemid 27242619)
2. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41. (Pubitemid 27385615)
3. Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53:506-10. (Pubitemid 24256979)
4. Vancheeswaran R, Azam A, Black C, et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76. (Pubitemid 24234664)
5. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
6. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15:2707-19. (Pubitemid 38691860)
7. Soldano S, Montagna P, Villaggio B, et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis 2009;68:599-602.
8. Shi-Wen X, Renzoni EA, Kennedy L, et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007;26:625-32. (Pubitemid 350186096)
9. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679-85. (Pubitemid 44830857)
10. Amiri F, Paradis P, Reudelhuber TL, et al. Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 2008;26:1102-9. (Pubitemid 351670501)
11. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110:2233-40. (Pubitemid 39372507)
12. Lamas S, Michel T, Collins T, et al. Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. J Clin Invest 1992;90:879-87.
13. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
14. Saijonmaa O, Nyman T, Fyhrquist F. Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem Biophys Res Commun 1992;188:286-91.
15. Saijonmaa O, Nyman T, Pacek P, et al. Oncostatin M regulates endothelin-1 production in human endothelial cells. Am J Physiol 1998;275:H662-7.
16. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694-702. (Pubitemid 43985337)
17. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20. (Pubitemid 46399451)
18. Farina G, Lemaire R, Pancari P, et al. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009;68:435-41.
19. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008;3:e1452.
20. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010;62:580-8.
21. Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008;58:2163-73. (Pubitemid 351988110)
22. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7. (Pubitemid 34406754)
23. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007;25:419-41. (Pubitemid 46697913)
24. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
25. Farina G, Lemaire R, Korn JH, et al. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006;25:213-22. (Pubitemid 43729069)
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
27. Kolumam GA, Thomas S, Thompson LJ, et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005;202:637-50. (Pubitemid 41248415)
28. Zeuke S, Ulmer AJ, Kusumoto S, et al. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002;56:126-34. (Pubitemid 35247809)
29. Cekic C, Casella CR, Eaves CA, et al. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 2009;284:31982-91.
30. Imaizumi T, Yoshida H, Nishi N, et al. Double-stranded RNA induces galectin-9 in vascular endothelial cells: involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 2007;17:12C-5C.
31. Doyle S, Vaidya S, O'Connell R, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002;17:251-63. (Pubitemid 35279547)
32. Farina GA, York MR, Di Marzio M, et al. Poly(I:C) Drives Type I IFN- and TGFβ-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis. J Invest Dermatol 2010;130:2583-93.
33. Kalali BN, Köllisch G, Mages J, et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol 2008;181:2694-704.
34. McCartney S, Vermi W, Gilfillan S, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009;206:2967-76.
35. Miyake T, Kumagai Y, Kato H, et al. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009;183:2522-8.
36. Wörnle M, Sauter M, Kastenmüller K, et al. Novel role of toll-like receptor 3, RIG-I and MDA5 in poly (I:C) RNA-induced mesothelial inflammation. Mol Cell Biochem 2009;322:193-206.
37. Karikó K, Bhuyan P, Capodici J, et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004;172:6545-9. (Pubitemid 38669088)
38. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-7. (Pubitemid 351483358)
39. Kumar H, Koyama S, Ishii KJ, et al. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 2008;180:683-7.
40. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2003;42:191-3. (Pubitemid 36131592)
41. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93. (Pubitemid 39643947)
42. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
43. Omagari D, Mikami Y, Suguro H, et al. Poly I:C-induced expression of intercellular adhesion molecule-1 in intestinal epithelial cells. Clin Exp Immunol 2009;156:294-302.
44. Orita T, Kimura K, Zhou H, et al. Poly(I:C)-Induced Adhesion Molecule Expression Mediated by NF-{kappa}B and Phosphoinositide 3-Kinase-Akt Signaling Pathways in Human Corneal Fibroblasts. Invest Ophthalmol Vis Sci 2010 ;51:5012-8.
45. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003;4:161-7. (Pubitemid 36193018)
46. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-72. (Pubitemid 36899248)
47. Harari OA, Alcaide P, Ahl D, et al. Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res 2006;98:1134-40. (Pubitemid 43948099)
48. Spirig R, Potapova I, Shaw-Boden J, et al. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol Immunol 2009;46:3178-82.
49. Groskreutz DJ, Monick MM, Powers LS, et al. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006;176:1733-40. (Pubitemid 43134318)
50. Tissari J, Sirén J, Meri S, et al. IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 2005;174:4289-94. (Pubitemid 40396010)
51. Jorgenson RL, Young SL, Lesmeister MJ, et al. Human endometrial epithelial cells cyclically express Toll-like receptor 3 (TLR3) and exhibit TLR3-dependent responses to dsRNA. Hum Immunol 2005;66:469-82. (Pubitemid 40797545)
52. Lim DM, Narasimhan S, Michaylira CZ, et al. TLR3-mediated NF-{kappa}B signaling in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2009;297:G1172-80.
53. Ueta M, Hamuro J, Kiyono H, et al. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun 2005;331:285-94. (Pubitemid 40545174)
54. Cavassani KA, Ishii M, Wen H, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008;205:2609-21.
55. Julkunen H, Saijonmaa O, Grönhagen-Riska C, et al. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 1991;50:526-7.
56. Pache M, Schwarz HA, Kaiser HJ, et al. Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 2002;8:CR616-19.